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Abstract
Background:  The role of glucokinase (GCK) in the pathogenesis of maturity-onset diabetes of
the young is well established. However, its role in the common form of type 2 diabetes is far from
convincing. We investigated the role of the G-to-A polymorphism in the hepatic GCK promoter
on insulin sensitivity and beta cell function in 63 normotensive Asian Indians with normal glucose
tolerance. As proposed by Matsuda and DeFronzo, hepatic insulin sensitivity (ISIH) and total body
insulin sensitivity (ISIM) were estimated from the oral glucose tolerance test. Beta cell function was
estimated using %B from the Homeostasis Model Assessment and insulingenic index (dI/dG).
Result:  We identified 38 GG, 24 GA, and one AA subjects. The AA subject was pooled with the
GA subjects during the analysis. No difference was noted in the demographic features between the
two genotypic groups (GG vs. GA/AA). Compared to the GG group, the GA/AA group had a lower
ISIH (p=0.002), a lower ISIM (p=0.009), a higher %B (p=0.014), and a higher dI/dG (p=0.030).
Multivariate  analysis  revealed  that  this  polymorphism  is an  independent  determinant  for ISI H
(p=0.019) and along with age, waist-hip ratio, gender, and diastolic blood pressure accounted for
5 1 . 5 %  o f  t h e  va r i a t i o n  o f  I S I H.  However,  this  polymorphism  was  a  weak,  but  independent
determinant for ISIM (p=0.089) and %B (p=0.083). Furthermore, it had no independent effect on
dI/dG (p=0.135).
Conclusions:  These data suggest that the G-to-A polymorphism in the hepatic GCK promoter
is associated with hepatic insulin resistance in Asian Indians.
Introduction
Glucokinase (GCK) was originally proposed to be a glu-
cose sensor and metabolic signal generator in pancreatic
beta cells and hepatocytes [1]. The discoveries of a link-
age and subsequent identification of mutated GCK genes
[2,3] in families with maturity-onset diabetes of the
young (MODY) provide the strongest evidence for a cru-
cial role of GCK in the pathogenesis of MODY [1]. How-
ever, the structural mutations (missense, nonsense
mutation, or mutations affecting the splicing mecha-
nism) of GCK were only found in less than 1% of patients
with type 2 diabetes [4]. Thus, the mutated GCKs do not
play a key role in the pathogenesis of most forms of dia-
betes.
Nonetheless, some studies suggest that defective liver
GCK may play a role in the pathogenesis of insulin resist-
ance and type 2 diabetes [5]. In patients with type 2 dia-
betes who underwent elective cholecystectomy, hepatic
GCK activity was decreased by about 50% in obese dia-
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betic subjects compared to lean controls and obese con-
trols [5]. Hyperglycemia in animals has been shown to
decrease hepatic GCK activity, which can be reversed by
treatment with insulin [6]. We previously reported a G-
to-A polymorphism at the nucleotide position -258 of the
hepatic GCK promoter [7]. It occurred within a fragment
that was completely conserved between human and rat
[8,9]. The basic motif surrounding this variant was al-
most identical to a well-studied insulin responsive se-
quence (IRS) of the phosphoenolpyruvate carboxykinase
(PEPCK) gene [10]. Since hepatic GCK is regulated by in-
sulin [9], we hypothesized that this polymorphism could
be related to insulin resistance.
Results
We studied the hepatic GCK promoter polymorphism in
63 normotensive Asian Indians with normal glucose tol-
erance (Table 1 Clinical characteristics of the studied
subjects). Since insulin sensitivity is impaired in non-di-
abetic subjects with essential hypertension [11], only
those with normal blood pressure (< 140/90 mmHg)
were enrolled into the study. Since impaired glucose tol-
erance and overt diabetes are associated with insulin re-
sistance and since glucose toxicity could affect beta cell
function and insulin sensitivity [12], only those subjects
with a fasting plasma glucose concentration less than 6.1
mM, interval plasma glucose concentrations less than
11.1 mM, and a two-hour plasma glucose concentration
less than 7.8 mM were enrolled in the study. By eliminat-
ing factors that contribute independently to insulin re-
sistance, such as hypertension and abnormal glucose
tolerance, any effect regarding genetic influence per se
becomes more apparent.
Their genotypes were determined using a PCR-RFLP as-
say. We identified 38 GG, 24 GA, and one AA subjects
with the allelic frequencies of 79% and 21%, respectively
for the G and A allele. The distribution of genotypes was
in compliance with the Hardy-Weinberg equilibrium
(p=0.537). Since only one AA subject was identified, this
subject was pooled with the GA subjects during the anal-
ysis. Both genotypic groups (GG vs. GA/AA) had similar
demographic features (Table 2 Demographic features
and glycemic parameters by genotypes). During an
OGTT, the GA/AA group had a lower plasma glucose
concentration at 90 minutes than the GG group
(p=0.015, Figure 1) and higher plasma insulin concen-
trations at fasting and 60 minutes than the GG group
(p=0.003 and p=0.008, respectively).
Hepatic insulin sensitivity (ISIH) and whole body insulin
sensitivity (ISIM) were estimated from the OGTT as de-
scribed by Matsuda and DeFronzo [13]. Beta cell func-
tion (%B) was estimated from the HOMA [14] and dI/dG
(the ratio of the incremental response in insulin to that of
glucose during the first 30 minutes of the OGTT). The
GA/AA group had a lower ISIH (p=0.002) and ISIM
(p=0.009) than the GG group. This polymorphism ac-
counted for 14.4% and 10.7% of the variations in ISIH
and ISIM, respectively. In contrast, the GA/AA group had
better beta cell function, based on %B and dI/dG, com-
pared to GG group (Table 2). Demographic features and
glycemic parameters by genotypes).
Multivariate analysis showed that this polymorphism
was an independent determinant for ISIH (p=0.019) and
along with age, waist-hip ratio, gender, and diastolic
blood pressure explained 51.5% of the variation in ISIH
(Table 3  Stepwise regression analysis of the estimated
indices for insulin sensitivity and beta cell function).
However, systolic blood pressure and body mass index
had no impact on ISIH. Since hepatic insulin sensitivity
(ISIH) correlated very well with the whole body insulin
sensitivity (ISIM, p < 0.0001, r2=0.800), this polymor-
phism also had an independent but marginal impact on
ISIM (p=0.089). In contrast to hepatic insulin sensitivi-
ty, this polymorphism had less impact on beta cell func-
tion (9.5% and 7.5% of the variations in %B and dI/dG,
respectively). Multivariate analyses showed that this pol-
ymorphism was weakly associated with %B (p=0.083),
but not dI/dG (p=0.135).
Discussion
Our data show that the G-to-A polymorphism at the -258
nucletotide position of the hepatic GCK promoter is an
independent determinant for ISIH, but has only margin-
al impacts on ISIM and %B, and no impact on dI/dG. He-
patic and whole body insulin sensitivities are well
correlated to each other [13] and a better correlation be-
tween this polymorphism and ISIH was observed than
with ISIM. This suggests that the primary impact of this
polymorphism is on ISIH. Since all the subjects were glu-
Figure 1
Plasma glucose and insulin concentrations during oral glucose
tolerance tests Data present mean (glucose) or geometric
mean  (insulin)  with  95%  confidence  intervals.  ap=0.015;  b
p=0.003; c p=0.008.BMC Genetics (2000) 1:2 http://www.biomedcentral.com/1471-2156/1/2/
cose tolerant, their beta cell function will compensate for
the prevailing insulin resistance to maintain plasma glu-
cose concentration wthin a relatively narrow physiologi-
cal range. The observed differences in %B and dI/dG
between the two groups are most likely due to the com-
pensatory increase of beta cell response to the differenc-
es in insulin sensitivity. This interpretation is consistent
with the nature of this polymorphism, which occurs
within the hepatic GCK promoter and not in the beta cell
GCK promoter. Therefore, these results indicate that the
polymorphism mainly affects hepatic insulin sensitivity.
There are two forms of GCK: liver and islet. Although
each tissue has its own exon 1 and promoter, they share
common exons 2-10 [8]. The transcript of islet GCK is
regulated by glucose [15] while insulin is the key regula-
tor for hepatic GCK transcription [9]. Although substan-
tial work has been accomplished [16], the IRS has not
been identified within the hepatic GCK promoter. In con-
trast, the IRS of PEPCK has been mapped out and stud-
ied extensively, which is positively regulated by insulin
[10]. This polymorphism (G-to-A substitution) was not
only located in a region, which is highly similar to the IRS
of PEPCK, but also occurred at the base pair, which was
conserved between PEPCK and hepatic GCK and also
conserved between human and rat for both PEPCK and
hepatic GCK (Figure 2). This suggests that this base pair
may be very important in IRS. Transgenic mice withBMC Genetics (2000) 1:2 http://www.biomedcentral.com/1471-2156/1/2/
overexpressed PEPCK developed hyperinsulinemia [17].
Increased GCK gene copies in mice leads to increased he-
patic glucose metabolism and, consequently, a lower
plasma glucose concentration [18]. In addition, overex-
pression of human hepatic GCK in mice liver also results
in decreased glucose concentration and reduced body
weight [19]. Furthermore, mice that lack GCK only in the
liver are only mildly hyperglycemic but display pro-
nounced defects in both glycogen synthesis and glucose
turnover rate during a hyperglycemic clamp [20]. There-
fore, it is tempting to speculate that reduced expression
of hepatic GCK could lead to hepatic insulin resistance as
we observed in this study (seen in a lower ISIH for the
GA/AA subjects). Initially, glucose homeostasis is main-
tained by the compensatory hyperinsulinemia (as ob-
served from the higher plasma insulin concentration forBMC Genetics (2000) 1:2 http://www.biomedcentral.com/1471-2156/1/2/
the GA/AA subjects in this study) through an increase in
insulin secretion by the pancreatic beta cells, which was
also observed in this study (a higher %B and dI/dG for
the GA/AA subjects). However, the cause-effect relation-
ship between this polymorphism and insulin resistance
remains to be elucidated.
In conclusion, we demonstrated that the G-to-A poly-
morphism at the -258 nucleotide position of hepatic GCK
promoter is associated with hepatic insulin resistance in
normotensive and glucose tolerant subjects. To our
knowledge, this is the first study, which attempts to dis-
sect genetic influence among hepatic and whole body in-
sulin sensitivity and beta cell function. However, to
understand the molecular basis of insulin resistance of
this polymorphism requires further studies.
Materials and methods
Studied subjects:
The study was approved by the Institutional Review
Board and written informed consent was obtained at the
entry of the study from each participant. We confirm that
the study has complied with the recommendations of the
Declaration of Helsinki. Asian Indians who resided in the
metropolitan Los Angeles area were recruited from local
Indian temples. Only normotensive subjects, who were
not taking any medications, were included. Glucose tol-
erance was determined by an oral glucose tolerance test
(OGTT) after an overnight fast. The subjects were biolog-
ically unrelated. They were instructed to fast overnight
and not to take any medication before the study. Two
baseline blood samples were obtained at -10 and -5 min-
utes before an oral glucose challenge with 75 gm glucose.
Four additional blood samples were obtained at 30, 60,
90, and 120 minutes. Blood pressure was measured three
times with a mercury sphygmomanometer while the sub-
ject was in the seated position. The mean of the last two
measurements was used in the analysis.
Hepatic and whole body insulin sensitivity were estimat-
ed from the OGTT according to Matsuda and DeFronzo
[13]. They were calculated from the following formulae:
[405 / (fasting plasma concentration in µ U/mL X fasting
insulin concentration in mg/dL)], which was modified
from the Homeostasis Model Assessment (HOMA) [14],
for hepatic insulin sensitivity (ISIH) and [10,000 / (fast-
ing plasma glucose concentration in mg/dL X fasting in-
sulin concentration in µ U/mL X mean plasma glucose
concentration in mg/dL X mean plasma insulin concen-
tration in µ U/mL)^0.5] for whole body insulin sensitivi-
ty (ISIM). We also estimated beta cell function using %B
[20 X fasting plasma insulin concentration in µ U/mL /
(fasting plasma glucose concentration in mmol/L - 3.5)]
from the HOMA [14] and dI/dG [(plasma insulin con-
centration at 30 minutes - fasting plasma insulin concen-
tration in µ U/mL) / (plasma glucose concentration at 30
minutes - fasting plasma glucose concentration in
mmol/L)].
Laboratory methods:
Genomic DNA was extracted from the peripheral lym-
phocytes as described previously [21]. A polymerase
chain reaction-restriction fragment length polymor-
phism (PCR-RFLP) assay was developed for the 174-base
pair fragment containing nucleotide -411 to -238 of the
liver GCK promoter [8]. Since the substitution occurs
within a region that is not cut by any known restriction
enzyme, we created a de novo restriction site by placing
the reverse primer close to the site of variation and re-
placing one of the nucleotides in the reverse primer. By
substituting T with A at nucleotide -256 within the re-
verse primer, a de novo ACC I restriction site was created
when the molecular variation of G-to-A substitution was
present. The standard PCR reaction was a 10-µ l reaction
mixture containing 0.1 µ g of genomic DNA, 1 pmole of
each primer, 0.2 mM of dNTP, 2 mM of MgCl2, 1X PCR
buffer, and 0.25 U of Thermal stable Taq polymerase.
The PCR was performed with an initial denaturation at
94° C for 5 minutes, 35 cycles of denaturation at 94° C for
30 seconds, annealing at 62° C for 30 seconds, extension
at 72° C for 30 seconds, and then a final extension at 72° C
for 10 minutes. The forward primer was CAGACCCT-
GGATTGTATGAAATG and the reverse primer was
GGCTGCCTTGGCCACAGTA. The restriction digestion
Figure 2
Similarity of putative insulin regulatory sequence with known
insulin regulatory sequence of rat phosphoenolpyruvate car-
boxykinase (PEPCK) All the sequences shown are from the
coding strand of the respective gene promoter. The 5' end
positions are expressed relative to the transcription start site
(GenBank  accession: M90298  for  human  liver  glucokinase;
M24943 for rat liver glucokinase; K03243 for rat PEPCK).
Human  PEPCK  has  two  copies  of  insulin  regulatory
sequences in its promoter and the transcription start site has
not  been  mapped  yet  (Chiu  KC,  unpublished  data).  The
underlined A in the variant human liver glucokinase is the
position where the G-to-A substitution occurs. The blocked
area is conserved between human and rat and also between
PEPCK and glucokinase.BMC Genetics (2000) 1:2 http://www.biomedcentral.com/1471-2156/1/2/
was carried out in a 10 µ l reaction containing 2.5 µ l of
PCR reaction and 0.1 U of Acc I in the buffer supplied by
the vender (Promega Inc., Madison, WI, USA) at 37° C for
3 hours. The reaction was resolved on a 8% acrylamide
gel which was scored under a UV illuminator after stain-
ing with ethidium bromide. The wild type (G at nucle-
otide -258) was not cut by Acc I and was isolated as a
larger fragment (173 bp), while the variant (A at nucle-
otide -258) was cut by Acc I to produce a smaller frag-
ment (154 bp).
Statistical analysis:
Variables with skewed distributions were logarithmically
transformed before analysis. They were body mass in-
dex, waist-hip ratio, insulin concentrations, %S, ISIM,
%B, and dI/dG. Data were presented as means (or geo-
metric means when appropriate) with 95% confidence
intervals, unless otherwise specified. Two-sided t-tests
or chi-square tests were used to evaluate the differences
between the two groups. To examine the influence of
multiple variables on either insulin sensitivity or beta
cell function, multivariate analysis was performed with a
backward stepwise option. The probability to enter or to
remove was set at 0.10. A nominal P value of less than
0.05 was considered significant. SYSTAT 8.0 for Win-
dows from SPSS, Inc. (Chicago, Illinois) was used for the
statistical analyses.
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